ONLINE APPENDIX

Online Figure 1 Trial Profile. Of all patients who underwent percutaneous coronary intervention with DES during the study period, 3,224 patients were eligible. A total of 1,811 patients (56%) were enrolled and randomly assigned to the stent types. Two-year follow-up data was obtained from 1,810 patients (one patient withdrew consent). BMS=bare metal stent. DES=drug-eluting stent

Online Figure 2.

Patient-Reported Chest Pain at 1 and 2-Years (in Patients who Provided Chest Pain Information at Both Times). Patient-reported chest pain classified into 4 scores: 0= no chest pain at all; 1= chest pain only during most severe physical exertion; 2= chest pain at moderate physical effort (during moderate/normal daily activities); 3= chest pain during mild physical exertion or at rest. Panels A and B provide information about the presence and extent (i.e., pain score) of chest pain at 1 and 2-year follow-up in 1,572 patients, who were alive at 2-year follow-up and answered the chest pain questionnaire both times.

Online Table 1. Supplement II. Outcome of patients in whom longitudinal stent deformation had been observed (all Promus Element stent group).

CaseVessel and segment

Lesion characteristics

ACC/AHA StentProximal/ distal location in stent

Post-dilation of stent performed

Procedural consequences

DAPT use at

Consecutive adverse clinical events until

lesion class

size (mm)

2-year follow-up

2-year follow-up

1 LAD, midbifurcation

C 3.0 x 38 proximal +

additional proximal stent

– –lesion

2 RCA, midsevere

C 2.5 x 32 proximal +

additional proximal stent

– –calcification

3 LAD, prox.

bifurcationC 3.5 x

24 proximal +additional proximal stent

– –lesion

4 LAD, prox.

bifurcationC 2.25 x

16 proximal –additional proximal stent

– –lesion

5 LAD, prox.

severeC 2.25 x

22 proximal +additional proximal stent

– –calcification

6 Left main

bifurcationB2 3.5 x

16 proximal +postdilation

– –lesion of stent

7 RCA, distal

bifurcationC 2.5 x

32 proximal +additional proximal stent

+ –lesion

8 LAD, prox.

moderate calcification C 3.0 x

12 proximal +additional proximal stent

– –

9 RCA, midsevere

C 3.0 x 24 proximal +

postdilation– –

calcification of stent

ACC/AHA=American College of Cardiology/American Heart Association; LAD=left anterior descending artery; Prox.=proximal; RCA=right coronary artery; DAPT=dual antiplatelet therapy. +=yes; –=no.

Data except results of 2-year follow-up have previously been reported in: von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): A randomised, single-blind, multicentre, non-inferiority trial. Lancet 2014;383:413-23.

Outcome of patients in whom longitudinal stent deformation had been observed (all Promus Element stent group). ACC/AHA=American College of Cardiology/ American Heart Association; LAD=left anterior descending artery; Prox.=proximal; RCA=right coronary artery; DAPT=dual antiplatelet therapy. + = yes; – = no.

Online Table 2 (Supplement III). Anticoagulant Use at 1 and 2-Year Follow-up.

Total Resolute Integrity ZES

Promus Element EES p value

At 1 year N=1776 N=883 N=883

Ascal 1575 (88.7) 786 (89.0) 789 (88.4) 0.66

P2Y12 inhibitor 437 (24.2) 227 (25.7) 210 (23.5) 0.28

DAPT 1534 (86.4) 765 (86.6) 769 (86.1) 0.75

Vitamin K antagonist 195 (11.0) 90 (10.2) 105 (11.8) 0.29

At 2 years N=1753 N=872 N=881

Ascal 1523 (86.9) 760 (87.2) 763 (86.6) 0.73

P2Y12 inhibitor 205 (11.7) 102 (11.7) 103 (11.7) 1.00

DAPT 157 (9.0) 78 (8.9) 79 (9.0) 0.99

Vitamin K antagonist 214 (12.2) 98 (11.2) 116 (13.2) 0.22

Values are % (n/N). DAPT= dual-antiplatelet therapy. Analysis based on survivors at 1 and 2-year, respectively.